Atopic Dermatitis: A Review of Current Diagnostic Criteria and a Proposed Update to Management

Reynolds, Matthew; Gorelick, Joe; Bruno, Matthew

doi:10.36849/jdd.2020.4737

Cited by 17 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral antihistamines and systemic antimicrobials can be beneficial under specific circumstances [12]. Monoclonal antibodies, which represent a modern treatment strategy, are not yet implemented in the current US guidelines though they are included in the recent European guidelines [13,14].…”

Section: Discussionmentioning

confidence: 99%

Can Platelet-Rich Plasma Reduce the Burden of Inflammatory Skin Diseases Such as Psoriasis and Atopic Dermatitis?

Kauhl

Pototschnig

Paasch³

2021

Cureus

View full text Add to dashboard Cite

In this study, our aim was to investigate the clinical effects of platelet-rich plasma (PRP) on the skin of patients suffering from plaque psoriasis or atopic dermatitis. MethodsOver a period of 53 months, we treated a total of 40 patients for inflammatory skin diseases with PRP. All of these patients were included in this study; 5-6 ml of PRP were prepared with the autologous-conditioned plasma (ACP) double syringe and injected subdermally. Follow-ups were conducted at three, six, nine, and 12 weeks after treatment. Besides the lesion size, Psoriasis Area and Severity Index (PASI) and Eczema Area and Severity Index (EASI) were also calculated. Data were evaluated statistically at a significance level of p≤0.05. ResultsA total of 30 patients were treated for plaque psoriasis. The elbow area represented the most common area of treatment (17 cases). The average lesion size decreased from 8.2 cm² to 0.3 cm² (p<0.00001). Of note, 80% of all patients achieved complete remission (PASI100) at the last follow-up. The remaining 20% reached at least PASI70. Ten patients were treated for atopic dermatitis. In six cases, efflorescences on patients' arms were treated, and in four cases, patients' legs were treated. The average lesion size decreased from 8 cm² to 0.155 cm² (p<0.00001). Notably, 50% of all patients achieved complete remission (EASI100) at the last follow-up. The other half reached at least EASI70. In all cases, the lesion size decreased progressively. No adverse events were reported. ConclusionOur study revealed encouraging results for both psoriasis and atopic dermatitis. The autologous treatment was safe and effective in all patients. Further studies are required to validate these initial findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Can Platelet-Rich Plasma Reduce the Burden of Inflammatory Skin Diseases Such as Psoriasis and Atopic Dermatitis?

Kauhl

Pototschnig

Paasch³

2021

Cureus

View full text Add to dashboard Cite

show abstract

“…In these patients, MCA is usually more difficult to diagnose compared to acute severe systemic MCA. Examples are local allergic reactions to exogenous allergens and organ-related atopic disorders, such as allergic rhinoconjunctivitis, atopic dermatitis, urticaria, or allergic asthma [42][43][44][45][46]. In most of these patients, serum tryptase levels increase only slightly or do not increase over the individual's baseline.…”

Section: Clinical Manifestations and Laboratory Correlates Of Mcamentioning

confidence: 99%

Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022

Valent¹,

Hartmann²,

Bonadonna³

et al. 2022

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Mast cell activation syndromes (MCASs) are defined by systemic severe and recurrent mast cell activation, usually in form of anaphylaxis, a substantial, event-related increase of the serum tryptase level beyond the individual’s baseline and a response of the symptomatology to drugs directed against mast cells, mast cell-derived mediators, or mediator effects. A number of predisposing genetic conditions, underlying allergic and other hypersensitivity states, and related comorbidities can contribute to the clinical manifestation of MCASs. These conditions include hereditary alpha tryptasemia, mastocytosis with an expansion of clonal <i>KIT</i>-mutated mast cells, atopic diathesis, and overt IgE-dependent and IgE-independent allergies. Several of these conditions have overlapping definitions and diagnostic criteria and may also develop concomitantly in the same patient. However, although criteria and clinical features overlap, each of these conditions is characterized by a unique constellation of variables and diagnostic criteria. Since two, three, or more conditions can coexist in the same patient, with obvious clinical implications, it is of crucial importance to diagnose the variant of MCAS precisely and to take all accompanying, underlying and potentially complicating conditions, and comorbidities into account when establishing the management plan. Indeed, most of these patients require multidisciplinary investigations and only a personalized treatment approach can lead to an optimal management plan providing an optimal quality of life and low risk of anaphylaxis.

show abstract

“…Pruritus is not only a source of frustration for patients, but also an important cause of sleep disorders, and significantly impacts the quality of life both of patients and their families [ 6 , 7 ]. It is a fundamental symptom of AD and a primary component of most diagnostic criteria [ 8 ]. Both clinical trials and everyday practice use various assessment scales, such as the Numeric Rating Scale (e.g., Peak Pruritus Numerical Rating Scale or PP-NRS), Visual-Analogue Scale (VAS), Verbal Rating Scale (VRS) and the 5-D Itch Scale, to estimate the intensity or occurrence of pruritus [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis

Hołdrowicz,

Woźniacka

2024

JCM

View full text Add to dashboard Cite

Atopic dermatitis is a heterogenous inflammatory disease with high variety in terms of clinical symptoms and etiopathogenesis, occurring both in pediatric and adult populations. The clinical manifestation of atopic dermatitis varies depending on the age of patients, but all age groups share certain common features, such as a chronic and recurrent course of disease, pruritus, and a co-occurrence of atopic diseases in personal or family medical history. Treating pruritus is a high priority due to its incidence rate in atopic dermatitis and substantial impact on quality of life. In recent years, treatments with biological drugs have increased the range of therapeutic possibilities in atopic dermatitis. The aim of the study is to present the safety profile, efficacy, and effectiveness of various biological treatment methods for the therapy of pruritus in the course of atopic dermatitis.

show abstract

Atopic Dermatitis: A Review of Current Diagnostic Criteria and a Proposed Update to Management

Cited by 17 publications

References 0 publications

Can Platelet-Rich Plasma Reduce the Burden of Inflammatory Skin Diseases Such as Psoriasis and Atopic Dermatitis?

Can Platelet-Rich Plasma Reduce the Burden of Inflammatory Skin Diseases Such as Psoriasis and Atopic Dermatitis?

Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022

The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis

Contact Info

Product

Resources

About